Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 21 December 2020
Location: Virtual meeting
This extraordinary meeting is organised in the context of the evaluation of the COVID-19 vaccine BNT162b2 developed by BioNTech and Pfizer.
The aim of the meeting is to assess additional information received from the company upon request of the Agency and to conclude the evaluation, if possible.
The extraordinary meeting planned for 29 December to conclude the evaluation will be maintained if needed.
The Committee for Medicinal Products for Human Use (CHMP) is the committee that is responsible for preparing the Agency's opinions on all questions concerning human medicines.